Improved health outcomes with donepezil in moderate to severe Alzheimer's disease are associated with economic benefits

被引：0
|
作者：
Feldman, H
Gauthier, S
Hecker, J
Vellas, B
Hux, M
Emir, B
Subbiah, P
Mastey, V
机构：
[1] Pfizer Inc, New York, NY USA
[2] Innovus Res Inc, Burlington, ON, Canada
[3] Toulouse Univ, Alzheimers Ctr, Toulouse, France
[4] Repatriat Gen Hosp, Daw Pk, Australia
[5] McGill Ctr Studies Aging, Verdun, PQ, Canada
[6] UBC Hosp, Div Neurol, Vancouver, BC, Canada
来源：
NEUROBIOLOGY OF AGING | 2002年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
285
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [1] Donepezil benefits patients with moderate to severe Alzheimer's disease
    Watts, Geoff
    [J]. BRITISH MEDICAL JOURNAL, 2012, 344
  • [2] Economic evaluation of donepezil in moderate to severe Alzheimer disease
    van Hout, HPJ
    Bosmans, JE
    Stalman, WAB
    [J]. NEUROLOGY, 2005, 64 (07) : 1320 - 1320
  • [3] Economic evaluation of donepezil in moderate to severe Alzheimer disease
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Hux, M
    Xu, Y
    Schwam, EM
    Shah, S
    Mastey, V
    [J]. NEUROLOGY, 2004, 63 (04) : 644 - 650
  • [4] Severe Alzheimer's disease: benefits of donepezil therapy
    Winblad, Bengt
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2006, 18 : S25 - S31
  • [5] Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
    Howard, Robert
    McShane, Rupert
    Lindesay, James
    Ritchie, Craig
    Baldwin, Ashley
    Barber, Robert
    Burns, Alistair
    Dening, Tom
    Findlay, David
    Holmes, Clive
    Hughes, Alan
    Jacoby, Robin
    Jones, Rob
    Jones, Roy
    McKeith, Ian
    Macharouthu, Ajay
    O'Brien, John
    Passmore, Peter
    Sheehan, Bart
    Juszczak, Edmund
    Katona, Cornelius
    Hills, Robert
    Knapp, Martin
    Ballard, Clive
    Brown, Richard
    Banerjee, Sube
    Onions, Caroline
    Griffin, Mary
    Adams, Jessica
    Gray, Richard
    Johnson, Tony
    Bentham, Peter
    Phillips, Patrick
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (10): : 893 - 903
  • [6] Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease
    Shah, SN
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Hux, M
    Xu, Y
    Schwam, E
    Leaderer, M
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S208 - S208
  • [7] The benefits of donepezil in patients with moderate-to-severe Alzheimer's disease are independent of baseline dementia severity
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Xu, Y
    Ieni, J
    Schwam, E
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 258 - 258
  • [8] Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease
    Burke, David
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 156 (12) : JC6 - JC10
  • [9] Treatment benefits of donepezil in patients with severe Alzheimer's disease and their caregivers
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Ieni, J
    Xu, Y
    Schwam, E
    [J]. NEUROLOGY, 2005, 64 (06) : A105 - A105
  • [10] Pharmacoeconomic benefits of donepezil treatment in severe Alzheimer's disease.
    Feldman, H
    Gauthier, S
    Hecker, J
    Vellas, B
    Hux, M
    Xu, Y
    Schwam, E
    Leaderer, M
    Shah, SN
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : S149 - S150
12345